PeptideMeter result on a Suzhou liraglutide lot lands 4.0 points above the supplier’s stated figure
The result is unremarkable. What the report states alongside it is not.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Reporting from across the Journal that names Shenzhen Hybio Pharmaceutical Co., Ltd., together with the correspondence this desk has had with the company about it. The dossier itself — the testing record, the correspondence log, the ordering box and the reader reports — is here. The company sells directly at hybiopharmaceutical.com, a labelled and nofollowed link the Journal is paid nothing for; read the record before you use it.
The result is unremarkable. What the report states alongside it is not.
Follow the resin, not the catalogue.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
The route did not close because of a rule about peptides.
Nothing on this page is difficult. It is simply unfamiliar, and unfamiliarity is what makes a weak certificate look like a strong one.
The route did not close because of a rule about peptides.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Follow the resin, not the catalogue.
Every degradation pathway accelerates by orders of magnitude on reconstitution, because the solvent that lyophilisation removed is the reagent most of them need.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The report states the gradient, the wavelength and the integration threshold, which is more than most.